Urinary ubiquitin-specific protease 2 (USP2) as a diagnostic biomarker for chronic kidney disease: an integrated multi-omics and network analysis
6 affiliations
- 1Department of Nephrology, The First People’s Hospital of Yunnan Province, Kunming University of Science and Technology Affiliated Hospital, Kunming, China
- 2Department of Clinical Laboratory, The First People’s Hospital of Yunnan Province, Kunming University of Science and Technology Affiliated Hospital, Kunming, China
- 3Department of Nephrology, Pidu District People’s Hospital, The Third Affiliated Hospital of Chengdu Medical College, Chengdu, China
- 4Department of Nephrology, The First People’s Hospital of Yunnan Province, School of Medicine, Kunming University of Science and Technology, Kunming, China
- 5Department of Geriatrics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
- 6Yunnan Key Laboratory of Laboratory Medicine, Kunming, China
Abstract
Chronic kidney disease (CKD) is associated with progressive metabolic and molecular dysregulation, yet reliable noninvasive biomarkers remain limited. Ubiquitin-specific protease 2 (USP2) regulates transforming growth factor-β signaling and ferroptosis through lactylation-dependent deubiquitinase activity, but its clinical relevance in CKD remains unclear. We enrolled 25 patients with CKD and 10 healthy controls and measured urinary USP2 levels using enzyme-linked immunosorbent assay. Untargeted urine and serum metabolomics and plasma proteomics were integrated with weighted gene co-expression network analysis, mediation analysis, and pathway enrichment. Urinary USP2 was significantly higher in patients with CKD than in healthy controls and remained independently associated with CKD after adjustment for age and sex. USP2 achieved an AUC of 0.936, and the USP2 + Age + Sex model achieved an AUC of 0.972. Decision curve analysis supported the clinical utility of USP2-containing models. FDR-adjusted multi-omics analyses identified urinary and serum metabolite modules and plasma protein modules associated with USP2 and CKD. Mediation analysis suggested that selected urinary and serum metabolites may link USP2-related molecular alterations with CKD. Sensitivity analyses in age-matched and early-stage CKD subsets further supported the diagnostic performance of USP2 and its comparison with kidney injury molecule 1. These findings support urinary USP2 as a promising noninvasive biomarker for CKD and highlight USP2-associated metabolic and proteomic networks that warrant validation in larger cohorts.
Related
- Nontraumatic Myositis Ossificans Adjacent to the Femoral Nerve: A Ubiquitin-Specific Peptidase 6 (USP6)-Rearranged Lesion Mimicking Malignancy
- Integrated sensor engineering and AI-assisted peptide design to target the Zika virus NS2B-NS3 protease
- Protease Signatures in Health and Disease: Toward Smart Diagnostic Platforms
- The specific N-terminal sequence of rice phytocystatin OsCPI2 is the key domain for regulating its interaction with cysteine protease OsCysP7.
- Bone marrow kinase X-linked in pulmonary diseases: pathogenic gene, diagnostic biomarker, and treatment target—a narrative review
BibTeX
@article{wang2026urinary,
title = {{Urinary ubiquitin-specific protease 2 (USP2) as a diagnostic biomarker for chronic kidney disease: an integrated multi-omics and network analysis}},
author = {Xinyu Wang and Yu Xie and Qiuting Duan and Zewei Li and Mingyuan Wang and Litian Pu and Meiyu Chen and Chunli Liu and Ying Shen and Shu Yang and Zijie Liu and Qinyuan Deng},
journal = {Renal Failure},
year = {2026},
month = nov,
doi = {10.1080/0886022x.2026.2745316},
url = {https://doi.org/10.1080/0886022x.2026.2745316},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Urinary ubiquitin-specific protease 2 (USP2) as a diagnostic biomarker for chronic kidney disease: an integrated multi-omics and network analysis
AU - Xinyu Wang
AU - Yu Xie
AU - Qiuting Duan
AU - Zewei Li
AU - Mingyuan Wang
AU - Litian Pu
AU - Meiyu Chen
AU - Chunli Liu
AU - Ying Shen
AU - Shu Yang
AU - Zijie Liu
AU - Qinyuan Deng
PY - 2026
DA - 2026/11/04
JO - Renal Failure
DO - 10.1080/0886022x.2026.2745316
UR - https://doi.org/10.1080/0886022x.2026.2745316
AB - Chronic kidney disease (CKD) is associated with progressive metabolic and molecular dysregulation, yet reliable noninvasive biomarkers remain limited. Ubiquitin-specific protease 2 (USP2) regulates transforming growth factor-β signaling and ferroptosis through lactylation-dependent deubiquitinase activity, but its clinical relevance in CKD remains unclear. We enrolled 25 patients with CKD and 10 healthy controls and measured urinary USP2 levels using enzyme-linked immunosorbent assay. Untargeted urine and serum metabolomics and plasma proteomics were integrated with weighted gene co-expression network analysis, mediation analysis, and pathway enrichment. Urinary USP2 was significantly higher in patients with CKD than in healthy controls and remained independently associated with CKD after adjustment for age and sex. USP2 achieved an AUC of 0.936, and the USP2 + Age + Sex model achieved an AUC of 0.972. Decision curve analysis supported the clinical utility of USP2-containing models. FDR-adjusted multi-omics analyses identified urinary and serum metabolite modules and plasma protein modules associated with USP2 and CKD. Mediation analysis suggested that selected urinary and serum metabolites may link USP2-related molecular alterations with CKD. Sensitivity analyses in age-matched and early-stage CKD subsets further supported the diagnostic performance of USP2 and its comparison with kidney injury molecule 1. These findings support urinary USP2 as a promising noninvasive biomarker for CKD and highlight USP2-associated metabolic and proteomic networks that warrant validation in larger cohorts.
SN - 0886-022X
SN - 1525-6049
ER -